Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer
The combination of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.The purpose of this study is to confirm that the combination of these two drugs can benefit patients with advanced esophageal cancer.
Esophageal Neoplasms
DRUG: an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
PFS, Progression Free Survival, From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
OS, Overall Survival, From date of admission until the date of death from any cause, assessed up to 24 months
The combination of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.The purpose of this study is to confirm that the combination of these two drugs can benefit patients with advanced esophageal cancer.